IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023

Press Releases 14 November 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023

Press Releases 13 November 2023 11 mins read

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...

Press Releases 07 November 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023

Corporate 03 October 2023 5 mins read

Ipsen updates on QM-1114 regulatory process

Corporate 04 September 2023 5 mins read

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director

Corporate 21 August 2023 15 mins read

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Press Releases 18 July 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

Corporate 26 May 2023 7 mins read

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

Neuroscience 09 June 2022 6 mins read

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or...

Corporate 27 October 2021 3 mins read

Ipsen Pledges Ambitious Action on Climate Change